Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3539-3545

  Khwaja, Fatima S ^a   Quann, Emily J ^c   Pattabiraman, Nagarajan ^b   Wynne, Shehla ^a   Djakiew, Daniel ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARPROFEN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROTROPHIN RECEPTOR P75; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; NERVE GROWTH FACTOR RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL STRAIN 3T3; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

3T3 CELLS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; HUMANS; MALE; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 56249134909     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0512     Document Type: Article

References (32)

1. Chao MV. The p75 neurotrophin receptor. J Neurobiol 1994;25:1373-85.
2. Chapman BS. A region of the 75kD neurotrophin receptor homologous to the death domains of TNFR-1 and Fas. FEBS Lett 1995;374:216-20.
3. Pflug BR, Dionne CA, Kaplan DR, et al. Expression of the Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995;136:262-8.
4. Perez M, Regan T, Pflug B, et al. Loss of the low affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997;30:274-9.
5. Pflug BR, Onoda M, Lynch JH, et al. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992;52:5403-6.
6. NTR loss of the expression in human prostate tumor cells. Mol Carcinogenesis 2001;31:46-55.
7. NTR is a tumor suppressor in human prostate cancer. Anticancer Res 2001;21:3749-55.
8. NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 2002;98:1-7.
9. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis. Part II. J Natl Cancer Inst 1998;90:1609-14.
10. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 2001;94:613-8.
11. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-73.
12. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-4.
13. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proc 2002;77:219-23.
14. Drago JR, Murray C. Control of metastases in the Nb rat prostatic adenocarcinoma model. J Androl 1984;5:265-8.
15. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and growth of prostate cancer in vivo. J Urol 2000;164:820-4.
16. Pollard M, Chang CF. Investigations on prostatic adenocarcinomas in rats. Oncology 1977;34:129-33.
17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
18. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
19. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
20. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-9.
21. Wechter WJ, Kantoci D, Murray ED, Jr., et al. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997;57:4316-24.
22. Lim JT, Piazza, GA, Han EK, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharm 1999;58:1097-107.
23. NTR-dependent decreased survival of prostate tumor cells. Cancer Res 2007;67:3254-62.
24. NTR in prostate cancer cells. Cancer Res 2007;67:11402-10.
25. NTR tumor suppressor protein. Cancer Res 2004;64:6207-13.
26. Khwaja F, Tabassum A, Allen J, et al. The p75(NTR) tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem Biophys Res Commun 2006;341:1184-92.
27. Engel KH, Schultz F, Martin F, et al. Constitutive activation of mitogen-activated protein kinase-activated protein kinase 2 by mutation of phosphorylation sites and an A-helix motif. J Biol Chem 1995;270:27213-21.
28. NTR mediates a bifurcated signal transduction cascade through the NFκB and JNK pathways to inhibit cell survival. Exp Cell Res 2005;304:69-80.
29. NTR- regulated gene expression. Differentiation 2005;73:385-96.
30. Juo P, Kuo CJ, Reynolds, et al. Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997;17:24-35.
31. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
32. Gaestel M. MAPKAP kinases, MKs, two's company, three a crowd. Mol Cell Biol 2006;7:120-30.